Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04143490
Other study ID # ExerciseUC-2019
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date November 4, 2019
Est. completion date December 2025

Study information

Verified date January 2023
Source Manchester Metropolitan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the effects of moderate to high intensity exercise on gut function and inflammatory markers in patients with Ulcerative Colitis (UC), and to compare them with individuals of matched age who do not suffer from Inflammatory Bowel Disease. Participants will be asked to complete 60 minutes of continuous cycling at a moderate to high intensity followed by a three hour recovery period. Gastrointestinal function will be measured using a non-invasive breath test. Blood samples will be collected at multiple time-points during the visit and these samples will be measured for markers of immune function and intestinal integrity.


Description:

There is limited research on the effect of exercise on patients with Ulcerative Colitis. The aim of this investigation is to study the acute effects of moderate to high intensity exercise on gut function in patients with Ulcerative Colitis and to compare them with individuals of matched age who do not suffer from Inflammatory Bowel Disease. Patients in remission from disease activity and age and gender matched healthy control participants will be recruited from the general population. Participants will attend the laboratory on two occasions. The first visit will last approximately one hour and will include an exercise test to determine peak oxygen uptake capacity (VO2peak) which is an indicator of cardiorespiratory fitness. The second visit will last for approximately four and a half hours and will consist of a 60 minute continuous cycle on a stationary cycle ergometer at an intensity of 65% VO2peak followed by a recovery period. Gastric emptying rate of a commercially available sports drink will be measured and blood samples will be collected at regular time-points throughout the visit and analysed for concentrations of inflammatory markers and intestinal integrity/function.


Recruitment information / eligibility

Status Suspended
Enrollment 24
Est. completion date December 2025
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: For ulcerative colitis patients; - Currently in remission of disease (asymptomatic at time of experiment) - Less than 3 periods of disease activity (periods of symptomatic activity) in the last 12 months - No history of surgery to alleviate condition severity - Taking regular standard medication for control of condition - Adult less than 50 years due to effects of exercise in older age - Non-smokers - Regular exercisers (determined via verbal discussion) For healthy controls; - No history of disease (as assessed by standard medical screening questionnaire) - Adult less than 50 years due to effects of exercise in older age - Non-smokers - Regular exercisers (determined via verbal discussion) Exclusion Criteria: For ulcerative colitis patients; - Currently in active period of disease (symptomatic at time of experiment) - More than 3 periods of disease activity (periods of symptomatic activity) in the last 12 months - History of surgery to alleviate condition severity - Taking non-standard medication for control of condition - Adult more than 50 years of age - Under 18 years of age - Smokers - Sedentary or not regularly physically active (determined via verbal discussion) For healthy controls; - History of disease (as assessed by standard medical screening questionnaire) - Adult more than 50 years of age - Under 18 years of age - Smokers - Sedentary or not regularly physically active (determined via verbal discussion)

Study Design


Intervention

Other:
Exercise
60 minutes of continuous exercise at 65% VO2peak and drink ingestion

Locations

Country Name City State
United Kingdom Manchester Metropolitan University Manchester Greater Manchester

Sponsors (2)

Lead Sponsor Collaborator
Manchester Metropolitan University University of Manchester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in inflammatory markers or hormones Circulating concentrations of Interleukin-6, Tumor Necrosis Factor-alpha, C-reactive protein, glucagon like peptide 2 6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
Primary Area under the circulating concentration versus time curve (AUC) of inflammatory markers or hormones Responses of Interleukin-6, Tumor Necrosis Factor-alpha, C-reactive protein, glucagon like peptide 2 4.5 hours
Primary Change in intestinal epithelial damage and permeability markers Circulating concentrations of intestinal fatty acid binding protein and claudin-3 6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
Primary Area under the circulating concentration versus time curve (AUC) of intestinal epithelial damage and permeability markers Responses of intestinal fatty acid binding protein and claudin-3 4.5 hours
Primary Change in exercise induced endotoxaemia markers Circulating concentrations of plasma lipopolysaccharide 6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
Primary Area under the circulating concentration versus time curve (AUC) of exercise induced endotoxaemia markers Response of plasma lipopolysaccharide 4.5 hours
Primary Gastric emptying rate half time and time of maximal emptying rate Emptying rate of a commercially available sports drink from the stomach using the 13C breath test method 2 hours after ingestion of drink
Primary Change in ratio of 13C/12C in breath samples Gastric emptying profile of a commercially available sports drink from the stomach using the 13C breath test method 9 breath samples collected at baseline, then every 15 minutes after ingestion for 2 hours
Secondary Incidence and severity of gastrointestinal symptoms 10-point rating scale for gastrointestinal symptoms (Visual Analogue Scale modified). 19 item questionnaire with 5 subcategories (Overall gut discomfort, total gastrointestinal symptoms, upper gastrointestinal symptoms, lower gastrointestinal symptoms and other gastrointestinal symptoms). Scores for each item ranging from 0 (no symptom) to 10 (extremely severe symptoms causing exercise reduction, stopping, or complete withdrawal). Higher scores represent higher severity of symptoms. Immediately post-exercise bout and 3 hours post exercise.
Secondary Heart rate response Heart rate telemetry Every 5 minutes during 60 minute cycle
Secondary Disparity of subjective exertion and objective cardiorespiratory parameters Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and cardiopulmonary exercise testing variables of oxygen uptake, carbon dioxide expiration, ventilatory threshold, volume of air expired, and tidal volume (all parameters measured in L/min). Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Secondary Disparity of subjective exertion and objective heart rate Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and heart rate measured by telemetry Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Secondary Disparity of subjective exertion and breathing frequency Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and number of breaths per minute Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Secondary Disparity of subjective exertion and oxygen pulse Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and oxygen pulse calculated by dividing oxygen uptake by heart rate. Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Secondary Disparity of subjective exertion and respiratory exchange ratio Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and respiratory exchange ratio calculated by dividing carbon dioxide production by oxygen uptake. Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Secondary Disparity of subjective exertion and ventilatory efficiency Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and minute ventilation/carbon dioxide slope (VE/VCO2 slope). Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Secondary Subjective physical activity levels International Physical Activity Questionnaire (IPAQ). Answers to questions (time spent completing different physical activities) converted to Metabolic Equivalent (METs) hours per week. Minimum value of zero, no limit to maximum. Higher MET values indicate higher physical activity levels. Prior to experimental trial
Secondary Attitudes and beliefs towards physical activity Barriers to Physical Activity Questionnaire. 21 item questionnaire, each question rated from 0 (very unlikely) to 3 (very likely). Each item belongs to one of 7 categories relating to barriers to physical activity. Score totals greater than 5 indicate the category as being a significant barrier. Prior to experimental trial
Secondary Subjective health related quality of life: RAND 36-Item Short Form Health Survey (SF-36) RAND 36-Item Short Form Health Survey (SF-36). 36-item questionnaire covering 8 concepts; physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions, plus single item providing an indication of perceived change in health. Scores ranging from 0 to 100 for each concept with 100 indicating good health and 0 being poor health. Prior to experimental trial
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2